Synairgen plc (AIM: SNG)
London
· Delayed Price · Currency is GBP · Price in GBX
4.311
-0.249 (-5.46%)
Nov 7, 2024, 12:01 PM GMT+1
Synairgen Company Description
Synairgen plc discovers and develops drugs for respiratory diseases.
It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses.
Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc
Country | United Kingdom |
Founded | 2004 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 36 |
CEO | Richard Marsden |
Contact Details
Address: Mailpoint 810 Southampton, SO16 6YD United Kingdom | |
Phone | 44 23 8051 2800 |
Website | synairgen.com |
Stock Details
Ticker Symbol | SNG |
Exchange | London Stock Exchange AIM |
Fiscal Year | January - December |
Reporting Currency | GBP |
ISIN Number | GB00B0381Z20 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Richard Marsden | Chief Executive Officer |
Joseph Colliver | Chief Financial Officer |